Grima Matthew J, Vriens Bianca, Holt Peter J, Chemla Eric
1 St. George's Vascular Institute, St. George's University Hospital, NHS Foundation Trust, London - UK.
2 Cardiovascular and Cell Sciences Department, St. George's University of London, London - UK.
J Vasc Access. 2018 Jan;19(1):45-51. doi: 10.5301/jva.5000808.
All arteriovenous fistula/grafts options should be exhausted before haemodialysis is carried out via central venous catheters (CVC). CVCs carry high morbidity and mortality risks and in some patients, the central veins could be exhausted. In these patients, an arterioarterial prosthetic loop (AAPL) or straight graft can be the only option for haemodialysis. A systematic review was thus carried out to look at the use of arterioarterial graft for haemodialysis, with regards to dialysis adequacy, complications, and patency rates.
An electronic search was performed using the EMBASE and MEDLINE databases from inception until June 2017. Study retrieval was conducted according to PRISMA guidelines.
A total of eight studies published between 1976 and 2017 were identified for pooled analysis. The studies were retrospective cohort in design and reported data on 151 patients. Primary patency rate ranged from 67%-94.5% at six months to 54%-61% at 36 months, with secondary patency rates from 83%-93% at six months to 72%-87% at 36 months. All studies documented satisfactory haemodialysis. Although limited by the size of the cohort of patients studied, patients with end-to-side grafts did not suffer from distal ischaemia when the graft occluded unlike patients who had their graft sutured as end-to-end.
This review highlights the potential benefit of arterioarterial grafts for dialysis as an alternative vascular access option. As a result, this review calls for registry-based multicentre study to evaluate this treatment arm as an alternative option when all AVF/AVG options are exhausted.
在通过中心静脉导管(CVC)进行血液透析之前,应尝试所有动静脉内瘘/移植物选项。CVC具有较高的发病和死亡风险,并且在某些患者中,中心静脉可能无法再使用。对于这些患者,动脉-动脉人工血管袢(AAPL)或直型移植物可能是血液透析的唯一选择。因此,进行了一项系统评价,以研究动脉-动脉移植物在血液透析中的应用,包括透析充分性、并发症和通畅率。
使用EMBASE和MEDLINE数据库进行电子检索,检索时间从数据库建立至2017年6月。根据PRISMA指南进行文献检索。
共纳入1976年至2017年发表的8项研究进行汇总分析。这些研究为回顾性队列研究,报告了151例患者的数据。6个月时的初级通畅率为67%-94.5%,36个月时为54%-61%,次级通畅率6个月时为83%-93%,36个月时为72%-87%。所有研究均记录了满意的血液透析效果。尽管受研究患者队列规模的限制,但与端端吻合的移植物患者不同,端侧吻合移植物的患者在移植物闭塞时未出现远端缺血。
本综述强调了动脉-动脉移植物作为替代血管通路选项用于透析的潜在益处。因此,本综述呼吁开展基于注册的多中心研究,以评估当所有动静脉内瘘/动静脉移植物选项均用尽时,该治疗方法作为替代选项的情况。